European Congress of Rheumatology 2023 (EULAR 2023)
Milan, Italy 31 May 2023 - 03 June 2023
Real-world data back CV safety of JAK inhibitors
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
Real-world data back CV safety of JAK inhibitors
28 Jun 2023
SGLT2 inhibitors score big, this time in gout
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
SGLT2 inhibitors score big, this time in gout
22 Jun 2023
Novel drug STRIDES in the right direction for knee OA
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).
Novel drug STRIDES in the right direction for knee OA
21 Jun 2023
AI predicts early-stage rheumatoid arthritis using MRI scans
It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.
AI predicts early-stage rheumatoid arthritis using MRI scans
20 Jun 2023
Abatacept halts RA progression early in high-risk group
Treatment with abatacept for a year halts disease progression in high-risk patients presenting with signs of imminent onset of rheumatoid arthritis (RA) in the phase IIb APIPPRA trial.
Abatacept halts RA progression early in high-risk group
20 Jun 2023
Dual-target oral drug outperforms tofacitinib in RA treatment
The novel, highly selective dual JAK1/TYK2 inhibitor TLL-018 appears to have better efficacy than the currently approved JAK inhibitor tofacitinib in the treatment of patients with rheumatoid arthritis (RA), according to the results of a head-to-head trial presented at EULAR 2023.
